We investigated the impact of dimethyl fumarate (DMF), an oral therapy for relapsing multiple sclerosis (MS), on blood microRNA (miRNA) signatures and neurofilament light (NFL) levels. DMF normalized miR-660-5p and modulated various miRNAs associated with the NF-kB pathway. These alterations reached a peak 4–7 months after treatment. Notably, particular miRNAs correlated with high or low NFL levels, implying their potential role as markers of treatment efficacy. Our findings broaden the understanding of DMF's immunomodulatory effects and may aid in predicting treatment responses.

Original languageEnglish
Article number578145
JournalJournal of Neuroimmunology
Publication statusPublished - 15. Aug 2023


  • Dimethyl-fumarate (DMF)
  • miRNA
  • Multiple sclerosis
  • Neurofilament light chain (NFL)
  • NF-kB


Dive into the research topics of 'Whole blood miRNAs in relapsing MS patients treated with dimethyl fumarate in the phase 4 TREMEND trial'. Together they form a unique fingerprint.

Cite this